TARPON SPRINGS, Fla. — December 31, 2025 — Leads & Copy — Allarity Therapeutics, Inc. (NASDAQ: ALLR) issued a letter to shareholders from CEO Thomas H. Jensen, reflecting on the company’s progress in 2024 and 2025 and outlining plans for 2026.
Jensen expressed optimism and gratitude for shareholders’ support during a period of transformation and focused execution. Since becoming CEO two years ago, the company has centered its strategy on advancing stenoparib, a dual inhibitor of PARP and the WNT pathway, for advanced ovarian cancers and other difficult-to-treat cancers like recurrent Small Cell Lung Cancer.
In 2024, Allarity underwent a strategic reset, focusing exclusively on stenoparib by shedding legacy programs. This allowed the company to deepen its understanding of stenoparib’s mechanism of action and expand its potential beyond ovarian cancer. The FDA recently granted stenoparib Fast Track Designation.
The company also simplified its capital structure, regained compliance with Nasdaq listing standards, and resolved legacy matters with the SEC. Operationally, Allarity streamlined the organization, recruited experienced oncology leadership, and implemented cost-efficiency measures.
In 2025, Allarity focused on accelerating stenoparib toward FDA approval in ovarian cancer and extended its clinical potential to recurrent Small Cell Lung Cancer. Updated data presented at the AACR Special Conference on Ovarian Cancer showed that median Overall Survival had not been reached, with some patients remaining on therapy for over 30 months.
Allarity also began a new Phase 2 trial protocol and signed an agreement to explore stenoparib in a recurrent small cell lung cancer trial funded by the US Veteran’s administration. Collaborations with the Indiana Biosciences Research Institute (IBRI) are underway to further understand stenoparib’s role in blocking the WNT pathway.
The company advanced its DRP® companion diagnostic platform, entering into a new licensing and laboratory services agreement. Financially, Allarity maintained a disciplined operating model and made tactical use of its share repurchase capacity.
Looking ahead to 2026, Allarity aims to expand its enterprise value by advancing stenoparib toward approval, expanding its indications, and seeking additional opportunities.
Jensen thanked shareholders for their belief in the company’s mission, stating that the decisions made over the past two years have positioned Allarity to move forward as a capable and credible company focused on bringing better cancer therapies to patients.
Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. Allarity has secured exclusive global rights for its development and commercialization.
Allarity uses its drug-specific DRP® to select patients who may have a high likelihood of benefiting from a specific drug, enhancing the therapeutic benefit rate.
Thomas Pedersen
Carrotize PR & Communications
+45 6062 9390
tsp@carrotize.com
Source: Allarity Therapeutics
